Early Development & Translational Safety
Focus Areas
- •Defensible FIH dose rationale and escalation logic
- •Translational safety strategy embedded into protocol design
- •Independent senior safety oversight for emerging programs
- •Mechanistic interpretation of safety signals
- •Early benefit–risk assessment frameworks
Strategic Safety Interpretation
Decisions made during early clinical development have a disproportionate impact on asset value — yet they are often taken under conditions of profound uncertainty.
The limiting factor is rarely missing data, but rather how uncertainty is structured, contextualised, and translated into a defensible decision.
I support teams by developing translational safety strategies that connect non-clinical toxicology, mechanistic pharmacology, and early clinical signals into a coherent decision-ready understanding of human risk.
Scope of Support
Translational Safety Strategy
Integration of toxicology, pharmacology, and biomarkers to anticipate human safety risk and inform early development decisions.
Mechanistic & Biomarker Insight
Mechanistic interpretation of safety signals, distinguishing on-target effects from off-target or secondary findings.
Preclinical-to-Clinical Transition
Strategic advisory on IND/CTA safety packages, first-in-human dose selection, and escalation rationale.
Clinical Development Strategy
I transform translational safety to a foundation for protocol design, evidence generation, and governance discussions.
Early Benefit–Risk Assessment
I apply structured benefit–risk thinking tailored to early-stage assets, where evidence is incomplete and uncertainty is unavoidable.
By explicitly articulating risk acceptability, assumptions, and trade-offs, I help teams prioritise development options and make clearer choices even when data are still evolving.
- Early benefit and value hypotheses
- Contextualisation of emerging safety signals
- Scenario-based comparison of development options
Decision Governance
A key differentiator of my work is the focus on decision traceability.
I help teams make explicit how evidence, assumptions, and uncertainty are linked to decisions — creating a clear, defensible logic that stands up to internal governance, boards, and external stakeholders.
- Explicit documentation of uncertainty
- Clear logging of assumptions and dependencies
- Board- and investor-ready decision narratives